The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion

Reproductive Sciences

Volumn 15, Issue 8, 2008, Pages 846-852

  Gogoi, Radhika ^a   Kudla, Marek ^a   Gil, Orlando ^a   Fishman, David ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b TCH 528 ^*  (United States)

Author keywords

Androgen receptor; Ovarian cancer; Synthetic progestins

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; GELATINASE A; GELATINASE B; MEDROXYPROGESTERONE ACETATE;

ARTICLE; CANCER CELL; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ZYMOGRAPHY;

CELL LINE, TUMOR; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; OVARIAN NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 54349102345     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719108323446     Document Type: Article

References (32)

1. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987 ; 316: 650-655.
2. Risch HA Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998 ; 90: 1774-1786.
3. Kuhnel R., de Graaff J., Rao BR, Stolk JG Androgen receptor predominance in human ovarian carcinoma. J Steroid Biochem. 1987 ; 26: 393-397.
4. Li AJ, Baldwin RL, Karlan BY Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma. Clin Cancer Res. 2003 ; 9: 3667-3673.
5. Edmondson R., Monaghan J., Davies B. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer. 2002 ; 86: 879-885.
6. Syed V., Ulinski G., Mok S., Yiu G., Ho S. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 2001 ; 61: 6768-6776.
7. Kemppainen JA, Langley E., Wong CI, Bobseine K., Kelce WR, Wilson EM Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol. 1999 ; 13: 440-454.
8. Ghatge RP, Jacobsen BM, Schittone SA, Horwitz KB The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res. 2005 ; 7: R1036 - R1050.
9. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996 ; 14: 357-361.
10. Miller AA, Becher R., Schmidt CG Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer. J Cancer Res Clin Oncol. 1988 ; 114: 186-190.
11. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 ; 17: 1736-1744.
12. Birrell SN, Roder DM, Horsfall DJ, Bentel JM, Tilley WD Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression. J Clin Oncol. 1995 ; 13: 1572-1577.
13. Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol. 1995 ; 52: 541-546.
14. Horwitz KB, Pike AW, Gonzalez-Aller C., Fennessey PV Progesterone metabolism in T47Dco human breast cancer cells-II. Intracellular metabolic path of progesterone and synthetic progestins. J Steroid Biochem. 1986 ; 25: 911-916.
15. Fishman DA, Bafetti LM, Stack MS Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996 ; 16: 150-159.
16. Fishman DA, Liu Y., Ellerbroek SM, Stack MS Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001 ; 61: 3194-3199.
17. Wang FQ, So J., Reierstad S., Fishman DA Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005 ; 114: 19-31.
18. Liao X., Thrasher J., Pelling J., Holzbeierlein J., Sang Q., Li B. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology. 2003 ; 144: 1656-1663.
19. Simental JA, Sar M., Lane MV, French FS, Wilson EM Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem. 1991 ; 266: 510-518.
20. Richer JK, Lange CA, Manning NG, Owen G., Powell R., Horwitz KB Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem. 1998 ; 273: 31317-31326.
21. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. Jama. 1995 ; 274: 1926-1930.
22. Kemppainen JA, Lane MV, Sar M., Wilson EM Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem. 1992 ; 267: 968-974.
23. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 ; 17: 1736-1744.
24. Hamerlynck JV, Maskens AP, Mangioni C., et al. Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study. Gynecol Oncol. 1985 ; 22: 313-316.
25. Tumolo S., Rao BR, van der Burg ME, Guastalla JP, Renard J., Vermorken JB Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 1994 ; 30A: 911-914.
26. Birrell S., Butler L., Harris J., Buchanan G. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB. 2007 ; 21: 2285-2293.
27. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004 ; 21: 865-883.
28. Saner KJ, Welter BH, Zhang F., et al. Cloning and expression of a novel, truncated, progesterone receptor. Mol Cell Endocrinol. 2003 ; 200: 155-163.
29. So J., Wang FQ, Navari J., Schreher J., Fishman DA LPAinduced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol. 2005 ; 97: 870-878.
30. Ariztia EV, Lee CJ, Gogoi R., Fishman DA The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci. 2006 ; 43: 393-425.
31. Rabbani S., Mazar A. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am. 2001 ; 10: 393-415.
32. Di Nezza LA, Jobling T., Salamonsen LA Progestin suppresses matrix metalloproteinase production in endometrial cancer. Gynecol Oncol. 2003 ; 89: 325-333.